Ribometrix Presents First c-MYC Data Validating RNA-Targeting Platform and Demonstrates Synergistic Potential of eIF4E Program at AACR 2024
These data build on presentations at last year’s Society for Melanoma Research and San Antonio Breast Cancer Symposium .
- These data build on presentations at last year’s Society for Melanoma Research and San Antonio Breast Cancer Symposium .
- eIF4E is a main regulator and rate limiting factor for protein synthesis and is elevated in many kinds of tumors.
- Caused tumor regression in mouse models of aggressive melanoma, ER+ breast cancer and non-small cell lung cancers through combination treatment with SOC.
- “The ability to target RNA-binding proteins that regulate oncogenes is a powerful modality with the potential to address cancer indications with high unmet need.